Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - Ademi LLP is investigating Day One Biopharmaceuticals, Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Servier, which involves a cash payment of $21.50 per share, totaling approximately $2.5 billion in equity value [1] Group 1: Transaction Details - Day One stockholders will receive $21.50 per share in cash, amounting to a total equity value of around $2.5 billion [1] - The transaction agreement includes provisions that significantly limit competing offers for Day One, imposing a substantial penalty if a competing bid is accepted [1] Group 2: Investigation Focus - The investigation by Ademi LLP centers on the conduct of Day One's board of directors and whether they are meeting their fiduciary responsibilities to all shareholders [1] - Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual shareholder rights [1]